

a4
36. [A] The method of claim 32, further comprising a method of inhibiting
ER-dependent transcription in a breast cell of an mammal, comprising administering an
effective amount of an AIB1 polypeptide to the mammal.

a5
40. [A] The method of claim 32, further comprising a method of inhibiting
ER-dependent transcription in a cancer cell of a mammal, comprising administering an
effective amount of a peptide mimetic of an AIB1 polypeptide to the mammal.

a6
46. [A transgenic mouse wherein] The transgenic animal of claim 45, wherein
at least one copy of the pCIP gene has been functionally deleted.

a7
53. [A method of reducing proliferation of a cancer cell comprising
administering to the mammal a] The method of claim 32, wherein the compound which
inhibits interaction of AIB1 [with] comprises a molecule selected from the group consisting
of steroid receptors and nuclear co-factors.

Respectfully submitted,

KLARQUIST SPARKMAN CAMPBELL
LEIGH & WHINSTON, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391

By William D. Noonan
William D. Noonan
Registration No. 30,878

cc: Joseph K. Hemby, Jr. (WO # 101-98)
Paul Meltzer, M.D., Ph.D.
Ronald King, Ph.D.
S:\WPDOCS\WDN\NIH\50420\Preliminary.amd